Manchester Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Manchester Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.85K	Hold	11	–	–	﹤0.01%	1056
2026 Q1	$1.45K	Hold	11	–	–	﹤0.01%	1067
2025 Q4	$1.56K	Buy	11 +10	+1,000%	+$1.45K	﹤0.01%	1065
2025 Q3	$141	Sell	1 -1	-50%	-$135	﹤0.01%	1271
2025 Q2	$252	Sell	2 -1	-33%	-$115	﹤0.01%	1164
2025 Q1	$332	Hold	3	–	–	﹤0.01%	1103
2024 Q4	$410	Hold	3	–	–	﹤0.01%	1088
2024 Q3	$346	Hold	3	–	–	﹤0.01%	1105
2024 Q2	$414	Hold	3	–	–	﹤0.01%	1075
2024 Q1	$414	Buy	+3	New	+$410	﹤0.01%	956
2023 Q4	–	Sell	-3	Closed	-$338	–	1052
2023 Q3	$338	Buy	+3	New	+$316	﹤0.01%	928
2021 Q1	–	Sell	-6	Closed	-$1K	–	734
2020 Q4	$1K	Buy	6 +3	+100%	+$290	﹤0.01%	670
2020 Q3	$0	Buy	+3	New	+$347	﹤0.01%	642

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Manchester Capital Management's NBIX Position: Q2 2026 in Review

Manchester Capital Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 11 shares worth $1.85K. The position accounts for ﹤0.01% of the portfolio, ranked #1056.

Manchester Capital Management first reported a position in NBIX in Q3 2020 and has held it in 13 quarters since. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Manchester Capital Management held 11 shares of Neurocrine Biosciences worth $1.85K as of Q2 2026.
Manchester Capital Management left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #1056 holding.
Manchester Capital Management first reported a position in Neurocrine Biosciences in Q3 2020 and has held it in 13 quarters since.
779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.